| __timestamp | Amneal Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106735000 | 581800000 |
| Thursday, January 1, 2015 | 136870000 | 671900000 |
| Friday, January 1, 2016 | 204747000 | 876700000 |
| Sunday, January 1, 2017 | 191938000 | 857900000 |
| Monday, January 1, 2018 | 210451000 | 822200000 |
| Tuesday, January 1, 2019 | 202287000 | 778200000 |
| Wednesday, January 1, 2020 | 190585000 | 512600000 |
| Friday, January 1, 2021 | 209563000 | 681000000 |
| Saturday, January 1, 2022 | 200046000 | 662200000 |
| Sunday, January 1, 2023 | 167778000 | 910700000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Viatris Inc. and Amneal Pharmaceuticals, Inc. have shown distinct trajectories in their R&D investments. From 2014 to 2023, Viatris consistently outpaced Amneal, with its R&D expenses peaking at a staggering 910 million in 2023, marking a 56% increase from its 2014 spending. In contrast, Amneal's R&D expenditure saw a more modest growth, peaking at 210 million in 2018, before slightly declining to 168 million in 2023. This trend highlights Viatris's aggressive push towards innovation, while Amneal maintains a steady, albeit smaller, investment in R&D. As the pharmaceutical industry continues to evolve, these spending patterns may offer insights into each company's strategic priorities and potential market positioning.
R&D Insights: How AbbVie Inc. and Amneal Pharmaceuticals, Inc. Allocate Funds
AstraZeneca PLC vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
R&D Insights: How Incyte Corporation and Amneal Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation